180 related articles for article (PubMed ID: 33729583)
1. Regulatory news: Dojolvi (triheptanoin) as a source of calories and fatty acids in long-chain fatty acid oxidation disorders: FDA approval summary.
Zand D; Doan J; Yi S; Wang J; Ma L; Akinshola E; Chakder S; Meyer J; Pacanowski M; Johnson LL; Donohue K; Beitz J
J Inherit Metab Dis; 2021 May; 44(3):515-517. PubMed ID: 33729583
[No Abstract] [Full Text] [Related]
2. Effects of triheptanoin (UX007) in patients with long-chain fatty acid oxidation disorders: Results from an open-label, long-term extension study.
Vockley J; Burton B; Berry G; Longo N; Phillips J; Sanchez-Valle A; Chapman K; Tanpaiboon P; Grunewald S; Murphy E; Lu X; Cataldo J
J Inherit Metab Dis; 2021 Jan; 44(1):253-263. PubMed ID: 32885845
[TBL] [Abstract][Full Text] [Related]
3. Triheptanoin: First Approval.
Shirley M
Drugs; 2020 Oct; 80(15):1595-1600. PubMed ID: 32897506
[TBL] [Abstract][Full Text] [Related]
4. Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment--A retrospective chart review.
Vockley J; Marsden D; McCracken E; DeWard S; Barone A; Hsu K; Kakkis E
Mol Genet Metab; 2015; 116(1-2):53-60. PubMed ID: 26116311
[TBL] [Abstract][Full Text] [Related]
5. Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial.
Gillingham MB; Heitner SB; Martin J; Rose S; Goldstein A; El-Gharbawy AH; Deward S; Lasarev MR; Pollaro J; DeLany JP; Burchill LJ; Goodpaster B; Shoemaker J; Matern D; Harding CO; Vockley J
J Inherit Metab Dis; 2017 Nov; 40(6):831-843. PubMed ID: 28871440
[TBL] [Abstract][Full Text] [Related]
6. The Pharmacokinetics of Triheptanoin and Its Metabolites in Healthy Subjects and Patients With Long-Chain Fatty Acid Oxidation Disorders.
Lee SK; Gupta M; Shi J; McKeever K
Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1325-1334. PubMed ID: 33789001
[TBL] [Abstract][Full Text] [Related]
7. Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders.
Vockley J; Charrow J; Ganesh J; Eswara M; Diaz GA; McCracken E; Conway R; Enns GM; Starr J; Wang R; Abdenur JE; Sanchez-de-Toledo J; Marsden DL
Mol Genet Metab; 2016 Nov; 119(3):223-231. PubMed ID: 27590926
[TBL] [Abstract][Full Text] [Related]
8. Triheptanoin for the treatment of long-chain fatty acid oxidation disorders: Final results of an open-label, long-term extension study.
Vockley J; Burton BK; Berry G; Longo N; Phillips J; Sanchez-Valle A; Chapman KA; Tanpaiboon P; Grunewald S; Murphy E; Lu X; Rahman S; Ray K; Reineking B; Pisani L; Ramirez AN
J Inherit Metab Dis; 2023 Sep; 46(5):943-955. PubMed ID: 37276053
[TBL] [Abstract][Full Text] [Related]
9. Major clinical events and healthcare resource use among patients with long-chain fatty acid oxidation disorders in the United States: Results from LC-FAOD Odyssey program.
Yang E; Kruger E; Yin D; Mace K; Tierney M; Liao N; Cibelli E; Drozd D; Ross N; Deering KL; Herout P; Harshaw Q; Shillington A; Thomas N; Marsden D; Kritzer A; Vockley J
Mol Genet Metab; 2024 May; 142(1):108350. PubMed ID: 38458123
[TBL] [Abstract][Full Text] [Related]
10. UX007 for the treatment of long chain-fatty acid oxidation disorders: Safety and efficacy in children and adults following 24weeks of treatment.
Vockley J; Burton B; Berry GT; Longo N; Phillips J; Sanchez-Valle A; Tanpaiboon P; Grunewald S; Murphy E; Humphrey R; Mayhew J; Bowden A; Zhang L; Cataldo J; Marsden DL; Kakkis E
Mol Genet Metab; 2017 Apr; 120(4):370-377. PubMed ID: 28189603
[TBL] [Abstract][Full Text] [Related]
11. Triheptanoin: long-term effects in the very long-chain acyl-CoA dehydrogenase-deficient mouse.
Tucci S; Floegel U; Beermann F; Behringer S; Spiekerkoetter U
J Lipid Res; 2017 Jan; 58(1):196-207. PubMed ID: 27884962
[TBL] [Abstract][Full Text] [Related]
12. Results from a 78-week, single-arm, open-label phase 2 study to evaluate UX007 in pediatric and adult patients with severe long-chain fatty acid oxidation disorders (LC-FAOD).
Vockley J; Burton B; Berry GT; Longo N; Phillips J; Sanchez-Valle A; Tanpaiboon P; Grunewald S; Murphy E; Bowden A; Chen W; Chen CY; Cataldo J; Marsden D; Kakkis E
J Inherit Metab Dis; 2019 Jan; 42(1):169-177. PubMed ID: 30740733
[TBL] [Abstract][Full Text] [Related]
13. Cardiac tissue citric acid cycle intermediates in exercised very long-chain acyl-CoA dehydrogenase-deficient mice fed triheptanoin or medium-chain triglyceride.
Gaston G; Gangoiti JA; Winn S; Chan B; Barshop BA; Harding CO; Gillingham MB
J Inherit Metab Dis; 2020 Nov; 43(6):1232-1242. PubMed ID: 33448436
[TBL] [Abstract][Full Text] [Related]
14. Medium branched chain fatty acids improve the profile of tricarboxylic acid cycle intermediates in mitochondrial fatty acid β-oxidation deficient cells: A comparative study.
Karunanidhi A; Van't Land C; Rajasundaram D; Grings M; Vockley J; Mohsen AW
J Inherit Metab Dis; 2022 May; 45(3):541-556. PubMed ID: 35076099
[TBL] [Abstract][Full Text] [Related]
15. Heptanoic and medium branched-chain fatty acids as anaplerotic treatment for medium chain acyl-CoA dehydrogenase deficiency.
Karunanidhi A; Basu S; Zhao XJ; D'Annibale O; Van't Land C; Vockley J; Mohsen AW
Mol Genet Metab; 2023 Nov; 140(3):107689. PubMed ID: 37660571
[TBL] [Abstract][Full Text] [Related]
16. Concerning "Triheptanoin vs trioctanoin for long-chain fatty acid oxidation disorders: A double blinded, randomized controlled trial" by Gillingham et al.
Shoffner JM
J Inherit Metab Dis; 2019 May; 42(3):394-395. PubMed ID: 30838661
[No Abstract] [Full Text] [Related]
17. Higher dietary protein intake preserves lean body mass, lowers liver lipid deposition, and maintains metabolic control in participants with long-chain fatty acid oxidation disorders.
Gillingham MB; Elizondo G; Behrend A; Matern D; Schoeller DA; Harding CO; Purnell JQ
J Inherit Metab Dis; 2019 Sep; 42(5):857-869. PubMed ID: 31295363
[TBL] [Abstract][Full Text] [Related]
18. Anaplerotic treatment of long-chain fat oxidation disorders with triheptanoin: Review of 15 years Experience.
Roe CR; Brunengraber H
Mol Genet Metab; 2015 Dec; 116(4):260-8. PubMed ID: 26547562
[TBL] [Abstract][Full Text] [Related]
19. De novo fatty acid biosynthesis and elongation in very long-chain acyl-CoA dehydrogenase-deficient mice supplemented with odd or even medium-chain fatty acids.
Tucci S; Behringer S; Spiekerkoetter U
FEBS J; 2015 Nov; 282(21):4242-53. PubMed ID: 26284828
[TBL] [Abstract][Full Text] [Related]
20. Tutorial: Triheptanoin and Nutrition Management for Treatment of Long-Chain Fatty Acid Oxidation Disorders.
Norris MK; Scott AI; Sullivan S; Chang IJ; Lam C; Sun A; Hahn S; Thies JM; Gunnarson M; McKean KN; Merritt JL
JPEN J Parenter Enteral Nutr; 2021 Feb; 45(2):230-238. PubMed ID: 33085788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
